Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Response-Adapted Treatment in Early-Stage Extranodal NK/T-Cell Lymphoma
NCT07768943Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Sep 2026
- Primary completion
- Jun 2033
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by Fudan University. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT07768943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07768943.